Cantor Fitzgerald Initiates Coverage On Theratechnologies with Overweight Rating, Announces Price Target of $9
Cantor Fitzgerald analyst Louis Chen initiates coverage on Theratechnologies (NASDAQ:THTX) with a Overweight rating and announces Price Target of $9.
Theratechnologies Q3 Sales $20.80M Beat $20.65M Estimate
Theratechnologies (NASDAQ:THTX) reported quarterly sales of $20.80 million which beat the analyst consensus estimate of $20.65 million by 0.73 percent. This is a 16.51 percent increase over sales of $17.85 million the
Theratechnologies’ Trogarzo Approved By FDA For 30-Second Intravenous (IV) Push, Simplifying HIV Treatment For Heavily Treatment-Experienced Population
Reduces maintenance dose from a 15-minute IV infusion to a 30-second, undiluted IV push every two weeks
Safety profile of Trogarzo® IV push similar to that of IV infusion
New method of
AstraZeneca-Merck’s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October’s Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.
Theratechnologies Highlights Trogarzo Data At AIDS 2022; Co Says Data Shows Potential for Improved Treatment Regimens
New sub-analysis on Trogarzo clinical trial patients demonstrates that long-term viral suppression is not influenced by partially active agents.
Predictive pharmacokinetic modelling shows that new methods of
Theratechnologies Reports Will Focus Its Commercialization Activities On North American Territory Only, Will Cease Its Trogarzo Operations In Europe
Theratechnologies Inc. (Theratechnologies or Company) (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will focus
Theratechnologies Earnings Preview
Theratechnologies (NASDAQ:THTX) is set to give its latest quarterly earnings report on Wednesday, 2022-04-13. Here's what investors need to know before the announcement.
Analysts estimate that Theratechnologies will report an earnings per share (EPS) of $-0.07.